OR WAIT 15 SECS
© 2020 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2020 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
May 02, 2020
Many antibody-drug conjugate therapies are in the pipeline; however, only a handful have been approved. What are the bottlenecks?
March 02, 2020
Assays can provide a useful tool in determining the potential toxicity of drugs throughout the development cycle.
October 02, 2019
Establishing OEL data and ensuring appropriate engineering controls are crucial aspects of safe handling.
August 15, 2019
The latest research from GlobalData has revealed that more than two-thirds (69%) of CMOs high-containment facilities are based in the top five European Union countries and Switzerland.
August 02, 2019
Complex and potent molecules demand greater technical and regulatory expertise to ensure safe handling.
June 17, 2019
Two additional production lines expand Lonza’s HPAPI capacity at Visp, Switzerland facility.
June 02, 2019
Excipients and new processing techniques can make a real difference in the development of highly potent therapies.
April 17, 2019
The ChargePoint Single Use Passive and ChargeBag create a single-use system for contained and sterile transfer of pharmaceutical powders between process steps or facilities.
March 02, 2019
Understanding the API, delivery mechanism, and excipient functionality is essential to solving drug solubility challenges.
Bio/pharma companies facing new challenges in light of the increasing HPAPI market may benefit from outsourcing.